EIF3F and colorectal carcinoma: Indeed, our study demonstrated that a combination treatment of LGK974 and NCT503 leads to the high response rate in inhibiting eIF3f‐high CRC PDX model, which provided strong support for targeting eIF3f‐driven CRC through the combination treatment as a novel therapeutic strategy for CRC therapy.